Table 1.
Summary of study characteristics.
| Study characteristics | Number of study (%) | |
|---|---|---|
| n = | (%) | |
| Study design | ||
| Cohort | 2 | 8.7 |
| Cross-sectional | 21 | 91.3 |
| Study population | ||
| General public | 10 | 43.4 |
| Affected individuals | 5 | 21.7 |
| Healthcare workers | 14 | 31.3 |
| Sample size | ||
| 1–499 | 13 | 56.5 |
| 500–599 | 5 | 21.7 |
| 1,000–1,999 | 1 | 4.3 |
| >2,000 | 4 | 17.4 |
| Diseases | ||
| COVID-19 | 11 | 47.8 |
| SARS | 12 | 52.2 |
| Geographic location | ||
| China | 9 | 39.4 |
| Hong Kong | 5 | 21.7 |
| Taiwan | 3 | 13.0 |
| Singapore | 2 | 8.7 |
| India | 1 | 4.3 |
| Vietnam | 1 | 4.3 |
| South Korea | 1 | 4.3 |
| Canada | 1 | 4.3 |
| Psychological impact | ||
| Depression | 19 | N/A |
| Anxiety | 16 | N/A |
| Post-traumatic stress disorder | 5 | N/A |
| Stress | 6 | N/A |
| Aggression | 1 | N/A |
| Psychological symptoms | 1 | N/A |
| Sleep related problems | 1 | N/A |
| Others | 1 | N/A |